9/25/2023  5:29:54 PM Chg. -0.26 Volume Bid5:30:00 PM Ask5:30:00 PM Market Capitalization Dividend Y. P/E Ratio
36.94EUR -0.70% 130,403
Turnover: 2.34 mill.
-Bid Size: - -Ask Size: - 8.36 bill.EUR - -

Business description

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

Management board & Supervisory board

Thierry Bernard
Management board
Roland Sackers, Dr. Jonathan Sheldon, Dr. Thomas Schweins, Jean-Pascal Viola, Stephany Foster, Antonio Santos
Supervisory board
Lawrence A. Rosen, Dr. Metin Colpan, Dr. Toralf Haag, Elizabeth E. Tallett, Prof. Dr. Elaine Mardis, Prof. Dr. Ross L. Levine, Thomas Ebeling, Dr. Eva Pisa, Steve Rusckowski

Company data

Address: Spoorstraat 50,NL-5911 KJ Venlo
Phone: +31-77-320-8400
Fax: +31-77-320-8409
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 60.00%
IPO date: 9/25/1997

Investor relations

Name: John Gilardi
IR phone: +49-2103-29-11711
IR Fax: -
IR e-mail: john.gilardi@qiagen.com

Main Shareholders

BlackRock, Inc.
Sun Life Financial, Inc. (MFS)
The Vanguard Group, Inc.
State Street Corp.
Goldman Sachs & Co. LLC
Rue la Boetie SAS